Tim Vanmierlo
Overview
Explore the profile of Tim Vanmierlo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
1471
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Sin Y, Cameron R, Schepers M, MacLeod R, Wright T, Paes D, et al.
FEBS Lett
. 2024 May;
598(13):1591-1604.
PMID: 38724485
Inhibition of the cyclic-AMP degrading enzyme phosphodiesterase type 4 (PDE4) in the brains of animal models is protective in Alzheimer's disease (AD). We show for the first time that enzymes...
12.
Tiane A, Somers V, Hellings N, van den Hove D, Vanmierlo T
Int J Mol Sci
. 2024 Mar;
25(6).
PMID: 38542441
One of the major challenges in multiple sclerosis (MS) is to accurately monitor and quantify disability over time. Thus, there is a pressing need to identify new biomarkers for disease...
13.
Veggel L, Mocking T, Sijben H, Liu R, Gorostiola Gonzalez M, Dilweg M, et al.
ACS Chem Neurosci
. 2024 Mar;
15(7):1424-1431.
PMID: 38478848
Excitatory amino acid transporters (EAATs) are important regulators of amino acid transport and in particular glutamate. Recently, more interest has arisen in these transporters in the context of neurodegenerative diseases....
14.
Willems E, Schepers M, Piccart E, Wolfs E, Hellings N, Ait-Tihyaty M, et al.
FASEB J
. 2024 Jan;
38(2):e23413.
PMID: 38243760
Sphingosine-1-phosphate receptor (S1PR) modulators are clinically used to treat relapse-remitting multiple sclerosis (MS) and the early phase of progressive MS when inflammation still prevails. In the periphery, S1PR modulators prevent...
15.
Hosseinkhani B, Duran G, Hoeks C, Hermans D, Schepers M, Baeten P, et al.
Fluids Barriers CNS
. 2023 Dec;
20(1):95.
PMID: 38114994
Autoreactive T lymphocytes crossing the blood-brain barrier (BBB) into the central nervous system (CNS) play a crucial role in the initiation of demyelination and neurodegeneration in multiple sclerosis (MS). Recently,...
16.
Koulousakis P, Willems E, Schepers M, Rombaut B, Prickaerts J, Vanmierlo T, et al.
J Alzheimers Dis
. 2023 Nov;
96(3):1207-1219.
PMID: 37927260
Background: Current treatment options for Alzheimer's disease (AD) are limited, inefficient, and often have serious side effects. Oxytocin is a neuropeptide implicated in a variety of central processes, such as...
17.
Nelissen E, Schepers M, Ponsaerts L, Foulquier S, Bronckaers A, Vanmierlo T, et al.
Pharmacol Res
. 2023 Oct;
197:106970.
PMID: 37884069
Vascular cognitive impairment (VCI) describes neurodegenerative disorders characterized by a vascular component. Pathologically, it involves decreased cerebral blood flow (CBF), white matter lesions, endothelial dysfunction, and blood-brain barrier (BBB) impairments....
18.
Roggeri A, Olivero G, Usai C, Vanmierlo T, Pittaluga A
Cells
. 2023 Oct;
12(19).
PMID: 37830557
This study provides evidence of the existence of presynaptic inhibitory sphingosine-1-phosphate receptor 1 (S1P1R) and facilitatory S1P3R in cortical nerve endings (synaptosomes) of healthy mice. The conclusion relies on the...
19.
Spaas J, Van der Stede T, de Jager S, van de Waterweg Berends A, Tiane A, Baelde H, et al.
Prog Neurobiol
. 2023 Sep;
231:102532.
PMID: 37774767
Multiple sclerosis (MS) pathology features autoimmune-driven neuroinflammation, demyelination, and failed remyelination. Carnosine is a histidine-containing dipeptide (HCD) with pluripotent homeostatic properties that is able to improve outcomes in an animal...
20.
Schepers M, Vanmierlo T
Neural Regen Res
. 2023 Sep;
19(3):493-494.
PMID: 37721269
No abstract available.